Real-world effectiveness of standard and alternative doravirine-containing regimens: long-term virological, immunological and metabolic outcomes in treatment-experienced people living with HIV

Background Doravirine (DOR) is a second-generation non-nucleoside reverse transcriptase inhibitor characterized by a favorable efficacy, safety, and drug-drug interaction profile. Although clinical trials have demonstrated the effectiveness of the triple, standard DOR-containing regimen (DOR/lamivudine/tenofovir disoproxil fumarate) in treatment-naïve and treatment-experienced people living with HIV (PLWH), real-world evidence regarding long-term outcomes after switching to standard or alternative DOR-containing regimens remains limited. This study aimed to evaluate the virological, immunological, metabolic, and safety outcomes of standard and alternative DOR-based antiretroviral therapy in a real-life cohort of PLWH. Methods Retrospective observational study including treatment-experienced PLWH who initiated a standard or alternative DOR-containing regimen. Viro-immunological and metabolic parameters were collected at baseline and 12 and 24 months after treatment switch. The primary endpoint was to evaluate treatment efficacy in terms of virological suppression and tolerability of the regimens. Secondary endpoints included changes in lymphocyte subsets and lipid profile with cardiovascular risk parameters. Results A total of 164 PLWH were included. All DOR-based regimens maintained high rates of virological suppression, with no significant loss of efficacy. Immunological parameters remained generally stable, with increases in absolute CD127+ and CD45RA+ T-cell counts and a reduction in CD38+CD8+ T cells. A significant improvement in lipid profile was observed after switching to DOR-based therapy, with reductions in total and LDL cholesterol in PLWH exposed to DOR-regimens containing TDF and with a higher proportion of PLWH achieving their target LDL cholesterol levels. Renal function remained stable, with no relevant changes in estimated glomerular filtration rate or proteinuria. Treatment discontinuation due to adverse events was uncommon. Conclusions In this real-life cohort of treatment-experienced PLWH, DOR-based regimens demonstrated sustained virological efficacy and tolerability over two years of follow-up. Switching to DOR was associated with favorable metabolic outcomes, particularly regarding lipid profile, and renal safety even among those exposed to TDF. Longitudinal changes in selected T-cell subsets were observed in this treatment-experienced cohort. Overall, these findings support DOR as an option for treatment optimization in PLWH requiring long-term antiretroviral management.

Authors

Institutions

Publication Details

Journal
Frontiers in Virology
Published
2026-11-18
DOI
https://doi.org/10.3389/fviro.2026.1988924
Primary Topic
HIV/AIDS drug development and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real-world effectiveness of standard and alternative doravirine-containing regimens: long-term virological, immunological and metabolic outcomes in treatment-experienced people living with HIV

Camilla Tincati, Giorgio Giannetta, Giulia Carla Marchetti, Martina Mazzoccoli et al.
5 links
Frontiers in Virology
HIV/AIDS drug development and treatment
article

Real-world effectiveness of standard and alternative doravirine-containing regimens: long-term virological, immunological and metabolic outcomes in treatment-experienced people living with HIV

Camilla Tincati, Giorgio Giannetta, Giulia Carla Marchetti, Martina Mazzoccoli, Teresa Bini, Riccardo Nardo, Lidia Gazzola, Laura Terracciano
article en

Abstract

Background Doravirine (DOR) is a second-generation non-nucleoside reverse transcriptase inhibitor characterized by a favorable efficacy, safety, and drug-drug interaction profile. Although clinical trials have demonstrated the effectiveness of the triple, standard DOR-containing regimen (DOR/lamivudine/tenofovir disoproxil fumarate) in treatment-naïve and treatment-experienced people living with HIV (PLWH), real-world evidence regarding long-term outcomes after switching to standard or alternative DOR-containing regimens remains limited. This study aimed to evaluate the virological, immunological, metabolic, and safety outcomes of standard and alternative DOR-based antiretroviral therapy in a real-life cohort of PLWH. Methods Retrospective observational study including treatment-experienced PLWH who initiated a standard or alternative DOR-containing regimen. Viro-immunological and metabolic parameters were collected at baseline and 12 and 24 months after treatment switch. The primary endpoint was to evaluate treatment efficacy in terms of virological suppression and tolerability of the regimens. Secondary endpoints included changes in lymphocyte subsets and lipid profile with cardiovascular risk parameters. Results A total of 164 PLWH were included. All DOR-based regimens maintained high rates of virological suppression, with no significant loss of efficacy. Immunological parameters remained generally stable, with increases in absolute CD127+ and CD45RA+ T-cell counts and a reduction in CD38+CD8+ T cells. A significant improvement in lipid profile was observed after switching to DOR-based therapy, with reductions in total and LDL cholesterol in PLWH exposed to DOR-regimens containing TDF and with a higher proportion of PLWH achieving their target LDL cholesterol levels. Renal function remained stable, with no relevant changes in estimated glomerular filtration rate or proteinuria. Treatment discontinuation due to adverse events was uncommon. Conclusions In this real-life cohort of treatment-experienced PLWH, DOR-based regimens demonstrated sustained virological efficacy and tolerability over two years of follow-up. Switching to DOR was associated with favorable metabolic outcomes, particularly regarding lipid profile, and renal safety even among those exposed to TDF. Longitudinal changes in selected T-cell subsets were observed in this treatment-experienced cohort. Overall, these findings support DOR as an option for treatment optimization in PLWH requiring long-term antiretroviral management.

Frontiers in VirologyVol. 6
AOL (United States) (US), University of Milan (IT), Azienda Socio Sanitaria Territoriale Lariana (IT), Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo (IT)
Good health and well-being
HIV/AIDS drug development and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon